Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

NCT07223983 · Active, not recruiting

Last updated 2026-09-22

This clinical trial is testing whether the medication semaglutide can help people who struggle with alcohol use disorder and have undergone weight-loss surgery.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 4 people

Who can join Ages 18+ · all sexes

Timeline Started 2026-03 · est. completion 2027-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07223983 ↗

Description as written by the study sponsor.

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

Treatments tested

Semaglutide 1.0 mg Drug

Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month (three months total).

Main thing measured	Percent weight change
Sponsor	Yale University
Conditions studied	Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07223983 ↗